Rocket Pharma Reports 3Q, Highlights Recent Progress

—Positive Phase 1 Study Results of RP-L201 for the Treatment of LAD-I Demonstrate Ongoing Efficacy, Durability and Validation of Rocket’s "Process B" Lentiviral Platform—

—Data Readouts in PKD, FA "Process B" and Danon Disease on Track for December—

—First Patient Treated in Higher Dose Cohort of Phase 1 Study of RP-A501 for the Treatment of Danon Disease—

—Strong Balance Sheet with $229 Million in Cash; Capitalized into 2Q 2022—

https://finance.yahoo.com/news/rocket-pharmaceuticals-reports-third-quarter-120000255.html